Day: April 1, 2024

-Project Continued Growth from Sales of AmnioWrap2®– -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the fourth quarter and twelve months ended December 31, 2023. Jason Matuszewski, CEO of BioStem, commented, “BioStem had an outstanding fourth quarter. Revenue reached $11.5 million, nearly 14 times higher than revenue of roughly $0.8 million for last year’s comparable quarter. This growth was driven by the successful commercial launch into the private office setting of AmnioWrap2, our innovative placental-derived allograft...

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and commercialize XTX301, a tumor-activated IL-12 Anticipates cash runway into the second quarter of 2025 WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) —  Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023. “With our recently announced partnership with Gilead for XTX301, our tumor-activated...

LOUISVILLE, Ky., April 01, 2024 (GLOBE NEWSWIRE) — LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems, health communications devices, and technology for the growing care economy, today announced that it has postponed the release of fourth-quarter and full-year 2023 financial results, and the conference call originally scheduled for April 1, 2024. The Company is filing an extension with the SEC to allow for more time to complete its 2023 Annual Report on Form 10-K. For more information, please visit https://investors.logicmark.com/ for all of the company’s press releases and SEC filings, as well as the eCommerce site at https://www.logicmark.com/. About UsLogicMark, Inc. (Nasdaq: LGMK) provides personal emergency response systems (PERS), health communications devices, and technologies to create a Connected...

-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market-Advanced regulatory and seed scale-up program for omega-3 Camelina-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023. “In 2023 we successfully executed our plan and achieved several key milestones that position Yield10 to build a sustainable products business based on engineered Camelina,” said Oliver...

BEIJING, April 01, 2024 (GLOBE NEWSWIRE) — Wah Fu Education Group Limited (“Wah Fu” or the “Company”) (Nasdaq:WAFU), a provider of online education and exam preparation services, as well as related training materials and technology solutions for both institutions and individuals, today announced its unaudited financial results for the six months ended September 30, 2023. Financial Highlights for the Six Months Ended September 30, 2023    For the Six Months EndedSeptember 30,  ($’000, except per share data)   2023     2022     % Change  Revenue   $ 3,648     $ 5,453     (33.1 )%Gross profit   $ 2,063     $ 2,788     (26.0 )%Gross margin     56.6 %     51.1 %   (5.4 )ppIncome (loss) from operations   $ 273     $ 1,117     (75.6 )%Operating profit (loss) margin     7.5 %     20.5 %   (13.0 )ppNet income (loss)   $ 125     $ 1,056     88.2 %Basic...